Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FDA, FVT

CIVCO Radiotherapy Announces FDA 510k Clearance and CE Mark of their Solstice SRS Immobilization System


CORALVILLE, Iowa, Oct. 15, 2018 /PRNewswire/ -- CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, is delighted to announce FDA 510k clearance and EU CE mark for their Solsticetm SRS Immobilization System. The product will be available for shipment following its display at the American Society for Radiation Oncology (ASTRO) Meeting taking place October 21-24, 2018 in San Antonio, Texas.

The Solstice SRS Immobilization System offers unique corrective pitch capability and positioning flexibility. It features customizable components that create a comfortable head and neck immobilization system for precise radiotherapy treatments to improve patient outcomes. The system is comprised of a carbon fiber head support, customizable cushion and dedicated thermoplastic mask designed for secure and simple attachment.

"The Solstice SRS Immobilization System is the only midline thermoplastic mask system on the market with variable pitch capability, increasing setup options in CT simulation and allowing positioning flexibility during treatment," commented John Steffen, Director of Product Management at CIVCO. "We are excited that clearance in the U.S. and EU CE marking opens opportunities for us to provide this unique solution to radiotherapy clinics to help improve patient outcomes."

For more information or to schedule a demo, visit www.CivcoRT.com or Booth #2833 during ASTRO.

About CIVCO Radiotherapy
CIVCO Radiotherapy has over 35 years' experience developing, manufacturing and providing high-quality, innovative, patient-centric solutions in radiotherapy. These solutions include: advanced patient immobilization and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products and advanced 6DOF robotic patient positioning. Corporate information is available at www.CivcoRT.com.

For further information, please contact:
Shelli Locklear
Sr. Marketing Manager
CIVCO Radiotherapy
Tel: 319-248-6619
[email protected]

COPYRIGHT © 2018. CIVCO IS A REGISTERED TRADEMARK OF CIVCO MEDICAL SOLUTIONS. SOLSTICE IS A TRADEMARK OF CIVCO. ALL PRODUCTS MAY NOT BE LICENSED IN ACCORDANCE WITH CANADIAN LAW. 2018C1441 REV. A

Video: https://www.youtube.com/watch?v=Igp3nO0uun4





These press releases may also interest you

at 01:51
OKX, a leading Web3 technology company, has issued updates for April 18, 2024. OKX Wallet Web Extension Expands to Include Luminex...

at 01:45
A promising start to 2024 - and to EQT's fourth decade "EQT started the year with the successful completion of two fundraises, EQT X and EQT Future, with total commitments of more than EUR 25 billion. Investment activity continued at a good pace and,...

at 01:31
Kerry Xuefeng Chen, Chairman and CEO of ATRenew (RERE.US), a leading technology-driven pre-owned consumer electronic transactions and services platform in China, discusses the huge potential for recycling of smartphones, electronics and even luxury...

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...

at 01:26
OKX, a leading Web3 technology company, has issued updates for April 18, 2024. OKX Wallet Now Integrated with Degen Chain OKX Wallet...

at 01:00
M360 Eurasia, hosted by the GSMA and with Host Sponsor Azercell, will return to Baku from 15-16 May 2024 at the JW Marriott Absheron Baku Hotel. M360 Eurasia convenes executives from leading corporations in mobile and vertical sectors, as well as...



News published on and distributed by: